A Phase 4 interventional study of treprostinil sodium in Hypertension, Pulmonary, sponsored by United Therapeutics. Terminated at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-01-03.
Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 36th largest by enrollment, is one of 4 that started in 2008, is one of 14 in phase 4, and was the 7th registered.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 4 started in 2008.
This study's enrollment of 7 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 36th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2008, is one of 11 in phase 4, and was the 7th registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life.
Pulmonary arterial hypertension (PAH), which is defined as an elevation in pulmonary arterial pressure and pulmonary vascular resistance, is a severe hemodynamic abnormality common to a variety of diseases and syndromes. Elevation in pulmonary arterial pressure causes an increase in right ventricular afterload, impairing right ventricular function and ultimately leading to inactivity and death. The goal of PAH treatment is to lengthen survival time, to ameliorate symptoms of PAH and to improve health related quality of life (HRQOL).
Remodulin® (treprostinil sodium), a stable analogue of prostacyclin, possesses potent pulmonary and systemic vasodilatory and platelet anti-aggregatory actions in vitro and in vivo. Recently, Remodulin received FDA approval for intravenous therapy based upon bioequivalence of the IV and SC routes of administration. Remodulin is more chemically stable than epoprostenol and may offer potential safety and convenience advantages compared to intravenous epoprostenol that may impact Health Related Quality of Life (HRQOL) and/or patient satisfaction. Unlike epoprostenol, Remodulin does not need to be mixed daily and is stable at room temperature eliminating the need for ice packs. Furthermore, since Remodulin remains in the body longer than epoprostenol (4 hrs instead of less than 5 minutes) there is less risk of cardiovascular collapse from a sudden interruption of infusion, such as a line clog. In an open-label study in Europe, patients who were using a type of portable medication pump called the CADD Legacy pump were rapidly switched from Flolan to Remodulin with no serious side effects. This study will examine effects of switching from therapy with epoprostenol or Flolan to IV Remodulin and compare changes in HRQOL and treatment satisfaction before and after rapid switch from epoprostenol to Remodulin in patients with pulmonary hypertension using the CADD legacy pump.
700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.
This study's enrollment of 7 is below the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Browse Pulmonary Arterial Hypertension studies →United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all subjects had switched from IV epoprostenol to IV treprostinil sodium
Drug: treprostinil sodium
rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
Also known as: Remodulin, Flolan
Change in Six Minute Walk Distance
Time frame: Baseline and Week 8
Change in WHO Functional Classification
Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms.
Time frame: Baseline and Week 8
Change in Borg Dyspnea Score Immediately After Six Minute Walk
The Borg Dyspnea Score is a 10-point scale rating the maximum level of dyspnea experienced after the Six-Minute Walk Test. Scores range from 0 (for the best condition) to 10 (for the worst condition).
Time frame: Baseline and Week 8
Change in Score on Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR)
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), a validated PAH-specific instrument consisting of 65 items used to assess symptoms, functioning and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning)and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.
Time frame: Baseline and Week 8
Change in Score on Treatment Satisfaction Questionnaire for Medication
The Treatment Satisfaction Questionnaire for Medication (TSQM), a validated generic measure of treatment satisfaction consisting of 14 Likert-response items comprising four domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. The TSQM was completed at baseline and at Week 8. The TSQM consists of 13 items that made up three specific scales (Effectiveness, Side effects, Convenience) and one global satisfaction scale. TSQM items are scaled using either a 5-point or 7-point scale. Five-point scales are used for unidimensional continua (e.g. extremely satisfied to not at all), while 7-point scales are used for bipolar continua(e.g., extremely positive to extremely negative. Non-neutral midpoints are used for 7-point scales, resulting in a greater range of positive response options than negative options for these items. Scale scores are transformed into scores ranging from 0 to 100, with a higher score indicating more satisfaction.
Time frame: Baseline and Week 8
Change in Total Weekly Time Spent With the Specific Activities Associated With Intravenous Remodulin Therapy Compared to Same Activities With Intravenous Epoprostenol
A Drug Administration Activities Diary, used by subjects to record in detail the amount of time (in minutes) spent on specifically-defined drug preparation/administration activities (e.g. diluting drug, preparing reservoir, and changing tubing), was completed over a 7-day period during the Screening period while on epoprostenol and repeated at Week 7 following transition to Remodulin. Drug Administration Activities Diary results are reported as average time per week spent on drug administration activities
Time frame: Baseline and Week 8
Change in PAH Signs and Symptoms- Fatigue
The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Change From in Signs and Symptoms of PAH- Edema
The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Change in Signs and Symptoms of PAH- Dyspnea
The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Change in Signs and Symptoms of PAH- Orthopnea
The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Change in Signs and Symptoms of PAH- Dizziness
The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Change in Signs and Symptoms of PAH- Syncope
The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Change in Signs and Symptoms of PAH- Chest Pain
The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.
Time frame: Baseline and Week 8
Patient Impression of Change Questionnaire
A Patient Global Impression of Change Questionnaire, which consists of three items that ask the subject to rate changes (much better, somewhat better, about the same, somewhat worse, much worse) in their symptoms of PAH, the amount of time spent on activities associated with preparing and administering PAH therapy, and their satisfaction with their PAH therapy since transitioning from epoprostenol to intravenous Remodulin was conducted at Week 8 only and responses are reported as frequency distributions.
Time frame: Week 8
The first subject was enrolled in March 2008. Given the limited availability of eligible subjects at the investigative center (stable PH patients on stable epoprostenol therapy) and competition for enrollment by other studies, after an extended recruitment period during which no new subjects were enrolled, the study was subsequently closed.
| Milestone | Treprostinil Sodium |
|---|---|
| Started | 7 |
| Completed | 6 |
| Not completed | 1 |
| Withdrew: Death | 1 |
| meter | Treprostinil Sodium |
|---|---|
| Change in Six Minute Walk Distance | -14 ± 63.7 |
Class I: No limitation of physical activity. Class II: Slight limitation of physical activity. Class III: Marked limitation of physical activity. Class IV: Inability to carry out any physical activity without symptoms.
| participants | Treprostinil Sodium |
|---|---|
| Improved | 0 |
| No change | 5 |
| Worsened | 1 |
The Borg Dyspnea Score is a 10-point scale rating the maximum level of dyspnea experienced after the Six-Minute Walk Test. Scores range from 0 (for the best condition) to 10 (for the worst condition).
| units on a scale | Treprostinil Sodium |
|---|---|
| Change in Borg Dyspnea Score Immediately After Six Minute Walk | 0.67 ± 0.52 |
The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), a validated PAH-specific instrument consisting of 65 items used to assess symptoms, functioning and quality of life. The questionnaire is divided into three sections; Symptoms (Scores 0-25; high scores indicate more symptoms), Activity (Score 0-30; low score indicates good functioning)and Quality of Life (0-25; high scores indicate poor QoL). The sum of these scores equates to the Total score (0-80). In the CAMPHOR scores, lower scores indicate improvements.
| units on a scale | Treprostinil Sodium |
|---|---|
| Symptom Score | -2.5 ± 2.0 |
| Activitity Score | -0.8 ± 2.6 |
| Quality of Life Score | -4.4 ± 6.7 |
| Total Score | -8.0 ± 8.9 |
The Treatment Satisfaction Questionnaire for Medication (TSQM), a validated generic measure of treatment satisfaction consisting of 14 Likert-response items comprising four domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. The TSQM was completed at baseline and at Week 8. The TSQM consists of 13 items that made up three specific scales (Effectiveness, Side effects, Convenience) and one global satisfaction scale. TSQM items are scaled using either a 5-point or 7-point scale. Five-point scales are used for unidimensional continua (e.g. extremely satisfied to not at all), while 7-point scales are used for bipolar continua(e.g., extremely positive to extremely negative. Non-neutral midpoints are used for 7-point scales, resulting in a greater range of positive response options than negative options for these items. Scale scores are transformed into scores ranging from 0 to 100, with a higher score indicating more satisfaction.
| units on a scale | Treprostinil Sodium |
|---|---|
| Effectiveness Score | -9.3 ± 13.0 |
| Side-Effects Score | 19.8 ± 28.9 |
| Convenience Score | 22.2 ± 12.2 |
| Global Satisfaction Score | -1.2 ± 21.4 |
A Drug Administration Activities Diary, used by subjects to record in detail the amount of time (in minutes) spent on specifically-defined drug preparation/administration activities (e.g. diluting drug, preparing reservoir, and changing tubing), was completed over a 7-day period during the Screening period while on epoprostenol and repeated at Week 7 following transition to Remodulin. Drug Administration Activities Diary results are reported as average time per week spent on drug administration activities
| minutes | Treprostinil Sodium |
|---|---|
| Gather/Set-up | -2.6 ± 4.0 |
| Prepare Drug | -39.4 ± 12.8 |
| Connect Drug | -5.0 ± 11.3 |
| Change Dressing | 0.0 ± 10.6 |
| Total Time | -44.0 ± 25.2 |
The presence or absence of fatigue was documented. If present, the intensity of fatigue was rated mild, moderate, or severe.
| participants | Treprostinil Sodium |
|---|---|
| Improved | 0 |
| No Change | 4 |
| Worsened | 2 |
The presence or absence of edema was documented. If present, the intensity of edema was rated mild, moderate, or severe.
| participants | Treprostinil Sodium |
|---|---|
| Improved | 0 |
| No Change | 3 |
| Worsened | 3 |
The presence or absence of dyspnea was documented. If present, the intensity of dyspnea was rated mild, moderate, or severe.
| participants | Treprostinil Sodium |
|---|---|
| Improved | 1 |
| No Change | 3 |
| Worsened | 2 |
The presence or absence of orthopnea was documented. If present, the intensity of orthopnea was rated mild, moderate, or severe.
| participants | Treprostinil Sodium |
|---|---|
| Improved | 0 |
| No Change | 4 |
| Worsened | 2 |
The presence or absence of dizziness was documented. If present, the intensity of dizziness was rated mild, moderate, or severe.
| participants | Treprostinil Sodium |
|---|---|
| Improved | 0 |
| No Change | 5 |
| Worsened | 1 |
The presence or absence of syncope was documented. If present, the intensity of syncope was rated mild, moderate, or severe.
| participants | Treprostinil Sodium |
|---|---|
| Improved | 0 |
| No Change | 6 |
| Worsened | 0 |
The presence or absence of chest pain was documented. If present, the intensity of chest pain was rated mild, moderate, or severe.
| participants | Treprostinil Sodium |
|---|---|
| Improved | 0 |
| No Change | 5 |
| Worsened | 1 |
A Patient Global Impression of Change Questionnaire, which consists of three items that ask the subject to rate changes (much better, somewhat better, about the same, somewhat worse, much worse) in their symptoms of PAH, the amount of time spent on activities associated with preparing and administering PAH therapy, and their satisfaction with their PAH therapy since transitioning from epoprostenol to intravenous Remodulin was conducted at Week 8 only and responses are reported as frequency distributions.
| participants | Treprostinil Sodium |
|---|---|
| Symptoms- Much Better | 0 |
| Symptoms-Somewhat Better | 2 |
| Symptoms- About the Same | 3 |
| Symptoms- Somewhat Worse | 1 |
| Symptoms-Much Worse | 0 |
| Time Spent- Much Less | 3 |
| Time Spent- Somewhat Less | 3 |
| Time Spent- About the Same | 0 |
| Time Spent- Somewhat More | 0 |
| Time Spent- Much More | 0 |
| Satisfaction- Much More Satisfied | 1 |
| Satisfaction- More Satisfied | 3 |
| Satisfaction- About the Same | 1 |
| Satisfaction- Less Satisfied | 1 |
| Satisfaction- Much Less Satisfied | 0 |
Collected over Adverse events were assessed upon initiation of Remodulin through to the end of study (Week 8). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treprostinil Sodium | — | 2/7 (28.6%) | 6/7 (85.7%) |
| Event | Treprostinil Sodium |
|---|---|
| Abdominal painGastrointestinal disorders | 1/7 |
| BacteraemiaInfections and infestations | 1/7 |
| DehydrationMetabolism and nutrition disorders | 1/7 |
| NauseaGastrointestinal disorders | 1/7 |
| VomitingGastrointestinal disorders | 1/7 |
| Event | Treprostinil Sodium |
|---|---|
| HeadacheNervous system disorders | 5/7 |
| NauseaGastrointestinal disorders | 3/7 |
| VomitingGastrointestinal disorders | 3/7 |
| DiarrhoeaGastrointestinal disorders | 3/7 |
| Pain in ExtremityMusculoskeletal and connective tissue disorders | 3/7 |
| AnxietyPsychiatric disorders | 2/7 |
| InsomniaPsychiatric disorders | 2/7 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/7 |
| Back PainMusculoskeletal and connective tissue disorders | 1/7 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/7 |
| Age, Categorical(Participants) | Treprostinil Sodium |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 7 |
| >=65 years | 0 |
| Age, Continuous(years) | Treprostinil Sodium |
|---|---|
| Mean | 43.6 ± 32-58 |
| Sex: Female, Male(Participants) | Treprostinil Sodium |
|---|---|
| Female | 5 |
| Male | 2 |
| Region of Enrollment(participants) | Treprostinil Sodium |
|---|---|
| United States | 7 |
| Pulmonary Arterial Hypertension (PAH) etiology(participants) | Treprostinil Sodium |
|---|---|
| Idiopathic PAH | 5 |
| Collagen Vascular Disease | 1 |
| Portal Hypertension | 1 |
| World Health Organization (WHO) functional Class at time of transition(participants) | Treprostinil Sodium |
|---|---|
| Class II | 5 |
| Class III | 2 |
| Baseline 6 Minute Walk Distance (6MWD)(meters) | Treprostinil Sodium |
|---|---|
| Mean | 466.6 (343 to 565) |
The record gives a start of Mar 2008, a primary completion of Jan 2010 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 3 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →